Metabolic Stability Assessment of Larotrectinib Using Liquid Chromatography Tandem Mass Spectrometry

INTRODUCTION: Larotrectinib (VITRAKVI) is an orally potent tropomyosin receptor kinase (Trk) inhibitor that acts by competitive inhibition of all corresponding receptor kinases. It demonstrated a marked response rate (75%) and robust anticancer activity in Trk fusion-positive patients. This response...

Descripción completa

Detalles Bibliográficos
Autores principales: Attwa, Mohamed W, Kadi, Adnan A, Darwish, Hany W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961173/
https://www.ncbi.nlm.nih.gov/pubmed/32021096
http://dx.doi.org/10.2147/DDDT.S235934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961173/
https://www.ncbi.nlm.nih.gov/pubmed/32021096
http://dx.doi.org/10.2147/DDDT.S235934

Ejemplares similares